Key Stats for Henry Schein Stock
- Past-Week Performance: -2.7%
- 52-Week Range: $60.6 to $89.3
- Current Price: $80.2
What Happened?
Henry Schein just delivered its strongest quarterly sales growth in 15 quarters, a breakout that reframes this dental and medical supplies distributor as a genuine recovery play, with revenue now at a four-year high of $13.2 billion after bottoming at $12.3 billion in fiscal 2023.
On February 24, the company reported Q4 revenue of $3.4 billion, up 7.7% year over year, beating the $3.35 billion consensus, while adjusted EPS of $1.34 topped the $1.30 estimate, confirming the revenue chart’s upward inflection from the 2023 trough is now showing up in the bottom line.
The sharpest number in the print was specialty products revenue, which covers high-margin dental implants and biomaterials, rising 14.6% to $422 million in Q4, driving the $13.2 billion full-year total that eclipses every revenue figure posted since at least fiscal 2021, while peer Align Technology also beat Q4 estimates on strong aligner demand, confirming the sector recovery is broad.
Meanwhile, outgoing Chairman Stanley Bergman filed two separate share disposal notices on February 27 and March 3, even as Henry Schein confirmed presentations at Leerink’s Global Healthcare Conference on March 9 and the Barclays 28th Annual Global Healthcare Conference on March 10, two back-to-back investor events that will put the new CEO Frederick Lowery in front of Wall Street for the first time.
Also, just yesterday, Henry Schein opened its Dallas Discovery Center in Southlake, Texas, an 8,300-square-foot integrated dental and medical training facility that physically embodies the company’s strategic push to align oral and overall health care under one commercial roof.
Stanley Bergman, outgoing Chairman and CEO, stated on the Q4 earnings call that “the momentum is good…just feeling good that we’re back in the market, attacking the markets, gaining market share in an environment where dentists are feeling pretty good,” directly tied to revenue hitting its highest point in at least four years and a leadership handoff now officially complete.
Incoming CEO Frederick Lowery’s 100-day listening tour, paired with $780 million in remaining buyback authorization and a BOLD+1 plan targeting over $125 million in annual run-rate operating income improvement by end of 2026, sets up a multi-year margin expansion story built on a revenue base that has now clearly turned the corner.
Wall Street’s Take on HSIC Stock
The Q4 beat and 15-quarter sales growth high signal a genuine inflection, not a one-quarter blip, as the BOLD+1 plan’s operating income targets now have real revenue momentum behind them to support delivery.
With revenue growing 4.1% to an estimated $13.7 billion in 2026 and normalized EPS climbing 7.1% to $5.32, Henry Schein’s earnings engine is accelerating off a base where EBITDA margins held steady at 8.4% through 2025 despite a turbulent dental market.
Henry Schein’s 7.7% Q4 revenue growth stands in sharp contrast to Dentsply Sirona, whose revenue declined from $4.2 billion in 2021 to $3.7 billion in 2025, confirming Henry Schein is gaining ground while its closest peer shrinks.
Regardless, Wall Street currently stands Henry Schein at 3 buys, 4 outperforms, 8 holds, and 1 sell across 14 analysts as of March 6, with a mean price target of $89.79, implying 12% upside from the current $80.17.
The target range runs from $61.00 on the low end to $104.00 on the high end; the low anchors to a scenario where household budget pressures stall the dental recovery and Lowery’s transition disrupts execution, while the $104.00 high prices in full BOLD+1 delivery and sustained specialty products momentum.
What Does the Valuation Model Say?
TIKR’s mid-case target of $98.99 implies 23.5% total return from current levels, driven by a 3.6% revenue CAGR and net income margin expansion from 4.6% to 4.9%, with the $125 million run-rate operating income improvement by end of 2026 as the key input justifying that margin assumption.
The market is pricing Henry Schein as a slow-growth distributor when the specialty products segment, covering high-margin implants and biomaterials, grew 14.6% in Q4 alone.
That segment’s growth rate stands in sharp contrast to the 3.6% blended revenue CAGR the model conservatively assumes, suggesting the market is underweighting the mix shift toward higher-margin businesses.
Management’s own target of over $200 million in operating income improvement over the next few years, backed by $780 million in remaining buyback authorization, signals this is a deliberate capital allocation story, not a valuation accident.
If household budget pressures deepen and dental patient volumes reverse, the 3% to 5% revenue growth guidance breaks and the BOLD+1 margin targets become unreachable.
Lowery’s presentations at Leerink’s Global Healthcare Conference on March 9 and Barclays on March 10 will be his first public appearances as CEO, and his tone on execution timelines will tell investors whether the transition is a catalyst or a risk.
Henry Schein is a recovering healthcare distributor with $125 million in targeted operating income improvements due by end of 2026 and a new CEO whose first 100 days begin now.
Should You Invest in Henry Schein, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up HSIC stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Henry Schein, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze HSIC stock on TIKR for Free →
